Adherex Technologies of Research Triangle Park, North Carolina, has inked a deal in-licensing GSK's oncology product eniluracil -- with GSK retaining an option to buy it back -- and giving GSK an option to license Adherex's lead biotechnology compound, ADH-1. GSK also made a $3 million equity investment in Adherex. GSK's options in the deal could be collectively worth up to $220 million in milestones plus royalties. Release